Open-Label, Multicenter Trial With IC41, a Therapeutic HCV Vaccine in Patients With Chronic HCV.

Trial Profile

Open-Label, Multicenter Trial With IC41, a Therapeutic HCV Vaccine in Patients With Chronic HCV.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2014

At a glance

  • Drugs IC 41 (Primary) ; Imiquimod
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Valneva
  • Most Recent Events

    • 05 Sep 2008 Status changed from active, no longer recruiting to completed.
    • 03 Sep 2008 Six month follow-up results reported in an Intercell media release.
    • 06 Feb 2008 Primary endpoint met, according to Intercell media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top